DJIA 17,959.44 154.64 0.87%
NASDAQ 4,781.42 16.04 0.34%
S&P 500 2,078.54 7.89 0.38%
market minute promo

Biogen Idec (NASDAQ: BIIB)

352.29 -8.38 (-2.32%)

REAL-TIME: Last trade at

Extended Hours: $352.29 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

BIIB $352.29 -2.32%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $352.00
Previous Close $360.67
Daily Range $345.23 - $356.65
52-Week Range $270.62 - $361.93
Market Cap $83.2B
P/E Ratio 34.15
Dividend (Yield) $0.00 (0.0%)
Volume 2,104,728
Average Daily Volume 1,855,723
Current FY EPS $13.47





Biogen Idec (BIIB) Description

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. Website:

News & Commentary

3 Drugmakers Facing a Pivotal 2015

Isis Pharmaceuticals, PTC Therapeutics, and GW Pharmaceuticals all expect 2015 to be a pivotal year in their drive toward becoming commercially viable entities. Should investors jump in before the catalysts spark?

Celgene Gets Positive CHMP Recommendation for Revlimid - Analyst Blog

Novo Nordisk's Tresiba Favored by CHMP for Expanded Use - Analyst Blog

Roche Loses A Little Luster Before Year-End

Jim Cramer Answers Twitter (TWTR) Questions on Gilead, WhiteWave Foods, and More

XLV, BIIB, ACT, AGN: Large Inflows Detected at ETF

Morning Market Losers

How to Invest Money: This Secret Could Save You Thousands

It's so simple that it's often overlooked.

Benzinga's Top #PreMarket Losers

3 Large Cap Biotech Stocks That Could Surprise Investors in 2015

Celgene Corp, Biogen Idec, and Medivation Inc. offer catalysts that could allow them to outpace estimates next year.

See More BIIB News...

BIIB's Top Competitors

BIIB $352.29 (-2.32%)
Current stock: BIIB
AMGN $164.53 (-3.31%)
Current stock: AMGN
GILD $92.90 (-14.34%)
Current stock: GILD
$0.00 (0.00%)
Current stock: